Lupus Nephritis FAQ
Lupus Nephritis FAQ
This page answers only the practical questions — what to send, what happens here, when travelling should be postponed, what it costs and how it is paid for, and how care continues afterwards. Every clinical question is answered by the other six pages in this guide, and this page does not repeat them.
What it costs
The initial assessment is free: records sent ahead are reviewed without charge, and the written opinion — including whether assessment here would add anything to the care you already receive — comes back before any payment is discussed. That ordering is deliberate. A large share of the enquiries we receive are answered in that letter, and no travel follows.
Where treatment here is appropriate, complete care in China typically runs at 30–50% of comparable care in Europe or the United States, consistently across conditions and programmes. For lupus nephritis the components are the assessment and its investigations — urine studies including microscopy and a quantitative protein measurement, blood tests including complement and antibodies, imaging, and where indicated a kidney biopsy with immunofluorescence and electron microscopy — followed by the medicines prescribed, the monitoring they require, and the follow-up measurements. An itemised quotation is provided once the records define what is actually needed, because a person whose workup is already complete and whose disease is in a stable class needs far less than one being assessed for the first time. What this page will not do is give a price without that: the range depends entirely on which of those applies.
How long the visit takes
This is stated in the written plan before anything is booked, because it depends on what the assessment turns up rather than on a standard package. An assessment built around urine and blood testing, imaging and consultation is arranged as outpatient visits and can be completed in a short stay. Where the findings call for a kidney biopsy, an extra day of observation is built in — the procedure itself is short, and the monitoring afterwards is what takes the time. Where immunosuppressive treatment is started or changed, the screening that must precede it is arranged first, which can add days rather than hours.
Because this is a disease followed over months, most people do not need to stay for the whole of a treatment course. The usual arrangement is a focused visit to establish the diagnosis and the plan, with the monitoring that follows carried out locally against targets we have written down for your team. The plan states the expected length of the visit before booking, so that flights, medicines and glucose or blood pressure monitoring are arranged against a number rather than an estimate.
Which records to send
Six groups of documents decide most of the assessment, and none requires translation beyond what our coordinators handle.
| What to send | What it answers |
|---|---|
| Urine results with dates, including any microscopy report | Whether inflammation is active, and whether blood and casts are present — the most direct sign that the kidney is involved |
| Protein measured quantitatively, ideally a series | How much is being lost and whether it is falling on treatment. Three measurements over six months are worth more than one precise one |
| Creatinine and filtration readings, as a series if possible | Where you are and whether function is moving |
| Complement, anti-dsDNA and other antibody results with dates | How active the immune system has been, and whether the trend precedes the clinical picture |
| Any kidney biopsy report in full, including microscopy, immunofluorescence and electron microscopy findings | The class, and the activity-chronicity balance — the findings the treatment is chosen from |
| Blood pressure readings including home ones, and the full medicine list with doses | Whether the modifiable contributors are controlled, and what can be adjusted or substituted |
Add the date your lupus was diagnosed, a summary of any treatment you have already had and how you responded, and anything you take that was not prescribed — supplements, herbal preparations, and painkillers bought over the counter. Photographs of clinic letters are acceptable to start. Where the urine has only ever been checked by dipstick, or the biopsy report states a class without the activity and chronicity indices, the opinion says so and names what to obtain locally first.
When travelling is safe — and when it is not
Postpone travel during an active flare, because the assessment here would be distorted by acute inflammation and the flight itself is more of a strain than usual; with any fever or active infection, and particularly so on immunosuppressive treatment; in the days immediately after a kidney biopsy, until the post-procedure observation period is complete; while blood pressure is severely uncontrolled; and during pregnancy in a person whose disease is active. These are not administrative cautions — each is a state in which either the assessment or the journey carries real risk.
For everyone else, travelling with this condition is routine with a few disciplines. Carry medicines in hand luggage, never in the hold, and carry more than the trip appears to need, split between two bags. Carry a doctor's letter covering the condition and every medicine, immunosuppressive ones included. Keep up hand hygiene and avoid close contact with people who are obviously unwell. Keep a copy of your latest results with the dates, because it is the single most useful document if you need care away from your own team. And know the sick-day rule that your team has written for you: that is the part of the plan it is worth reading before you need it.
Insurance and payment
We work with more than 30 commercial insurers on direct billing. Coordinators confirm coverage, exclusions and the paperwork required before arrival rather than after it — which matters here, because an assessment that turns out to need a kidney biopsy costs rather more than one that does not, and pre-authorisation should cover the possibility.
Patients without suitable coverage receive an itemised quotation and pay directly. Either way, costs are agreed in writing before travel, and the records review itself is free and happens first. Where an insurer requires a specific form or clinical letter, our department completes it as part of the assessment rather than as a billable extra.
What happens after you go home
You leave with a written summary in English covering the diagnosis and how it was established, the class on the biopsy with the activity and chronicity reading, the protein and blood pressure targets that apply in your case, every medicine and what each is for with the reduction schedule, the monitoring intervals, the vaccination and screening due dates, and a sick-day plan. Laboratory and pathology data are exported in standard formats, including the full biopsy report, so your local team continues the same series rather than starting a new one.
Follow-up continues with your own team, and our international department remains a written point of contact for questions about the opinion. Where a medicine was started here that needs monitoring — blood counts on mycophenolate or azathioprine, retinal screening on hydroxychloroquine, complement and antibody levels during a step-down — the summary states what to check and when, so that the first follow-up blood test at home is not a matter of guesswork. Where correspondence with your local doctor would help, we provide it in writing.
Coming with someone
A companion is welcome and often useful, particularly where the visit includes a biopsy or a change of medicines. Their practical value is in the room: a second person hearing the same explanation, holding the questions that were written down and then forgotten, and managing the logistics of a day that includes fasting blood tests and a procedure.
What we ask is that the companion be present for the consultation where a decision is being made — about a biopsy, or about a medicine whose monitoring changes — rather than only for travel. Coordinators arrange accommodation near the department and, where a companion is also the person who manages your medicines at home, we make sure they leave with the same written summary you do.
Where nobody can travel with you, the assessment runs the same way, and the written summary is the safeguard: everything that would have been said to a companion is in it, including the sick-day plan and the date of the next review.